Full Year 2025 Medartis Holding AG Earnings Call Transcript
Key Points
- Medartis Holding AG (MDRSF) achieved a total revenue of CHF269.3 million with an organic revenue growth of 15.7%, reaching the upper end of their guidance.
- The company successfully launched the TOUCH prosthesis in the US, with FDA approval achieved in August 2025, and plans to train an additional 300 surgeons in 2026.
- Medartis expanded its production capabilities significantly, moving from one to five production facilities, including a new facility in Curitiba, Brazil, and expansion in Geneva and Warsaw.
- The company completed two strategic acquisitions: NeoOrtho and KeriMedical, which are expected to drive future growth and innovation.
- Medartis is focusing on becoming a world leader in hand and wrist solutions, leveraging its strong market position in Europe and expanding in the US market.
- The company faced significant FX headwinds, with a negative impact of almost CHF8 million due to the weakening of the US dollar.
- US tariffs imposed a burden of about 90 basis points on the gross margin, with an expected increase in impact to CHF4 million in 2026.
- Medartis experienced a disruption in its US distribution network, particularly in Florida, which impacted growth in the region.
- The company is facing challenges in securing hospital contracts in the US, which can take up to nine months to finalize.
- Despite the positive growth outlook, the company anticipates further headwinds from tariffs and FX impacts, which could affect margins in the first half of 2026.
So we'll start. Good morning, ladies and gentlemen, whether you made it to [strictly] to Basel here by train or by car or if you're watching us behind the screen, thank you for being here to listen to our Medartis 2025 full year results story. A few practical questions before we get started. The presentation slide deck is our compass for today's meeting that was published this morning as alongside the annual report, the integrated annual report as well as the press release on 6:30 this morning.
I encourage you, especially for the annual report to explore them if you have the time. Now a brief important legal disclaimer on slide 2, you see the forward-looking statements that I'd also like you to take note of it. For today's program, we have two speakers lined up. You see them here on your right-hand side, Matthias Schupp, our CEO, who will open the strategic highlights of the year, what has been, in my opinion, a transformational year for the Medartis Group.
And then we have Peter Hackel, a very familiar face to many of you. He will then take us through the numbers behind the story. Once
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
